Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Net revenue	$ 155,753	$ 126,610
Operating expenses:
Cost of revenue	56,714	38,663
Research and development	58,196	32,778
Selling, general and administrative	63,482	43,186
Total operating expenses	178,392	114,627
(Loss) income from operations	(22,639)	11,983
Co-promotion income	3,750	0
Interest expense	(3,674)	0
Other income	198	62
(Loss) income before income taxes	(22,365)	12,045
Benefit from (provision for) income taxes	10,759	(4,474)
Net (loss) income	(11,606)	7,571
Net loss attributable to non-controlling interest	33	0
Net (loss) income attributable to The Medicines Company	$ (11,573)	$ 7,571
Basic earnings per common share attributable to The Medicines Company (USD per share)	$ (0.21)	$ 0.14
Diluted earnings per common share attributable to The Medicines Company (USD per share)	$ (0.21)	$ 0.14
Weighted average number of common shares outstanding:
Basic (shares)	54,047	54,037
Diluted (shares)	54,047	55,672